CD44 is reported to be involved in tumor invasion and metastasis. However, the role of cancer stem cell marker CD44 in bladder cancer still remains controversial. Hence, the correlations between CD44 expression and the clinicopathological features and the prognosis of bladder cancer were investigated. Publications using immunohistochemical methods were identified. The Cancer Genome Atlas (TCGA) data were also analyzed. The odds ratios (ORs) or hazard ratios (HRs) with their 95% confidence intervals (95% CIs) were calculated. 14 studies involving 1107 tissue samples were included. CD44 expression in bladder cancer was lower than in non-tumor tissue samples (OR = 0.14, P = 0.005), which was consistent with TCGA data. CD44 expression was correlated with advanced T stage (OR = 1.76, P = 0.029) and lymph node metastasis (OR = 4.09, P < 0.001). Multivariate survival analysis showed that CD44 expression was not linked to tumor-specific survival, overall survival, and recurrence/relapse-free survival, but was associated with disease failure (HR = 2.912, 95% CI = 1.51-5.61). No relationships of CD44 expression with the clinicopathological features and overall survival were found from TCGA data. Our finding suggested that CD44 expression may be correlated with progression, metastasis, and disease failure of bladder cancer. However, further large-scale studies are needed.Abbreviations: CD44: Cluster of Differentiation 44; CIs: Confidence Intervals; CSCs: Cancer Stem Cells; EMT: Epithelial-mesenchymal Transition; HRs: Hazard Ratios; ORs: Odds Ratios; TCGA: The Cancer Genome Atlas.

中文翻译：

---

CD44表达在膀胱癌中的临床病理和预后价值：一项基于荟萃分析和TCGA数据的研究。

据报道CD44参与肿瘤的侵袭和转移。但是，癌症干细胞标志物CD44在膀胱癌中的作用仍然存在争议。因此，研究了CD44表达与膀胱癌的临床病理特征和预后之间的相关性。确定了使用免疫组织化学方法的出版物。还分析了癌症基因组图谱（TCGA）数据。计算其95％置信区间（95％CI）的优势比（OR）或危险比（HRs）。包括14个研究，涉及1107个组织样本。膀胱癌中CD44的表达低于非肿瘤组织样品（OR = 0.14，P = 0.005），这与TCGA数据一致。CD44表达与晚期T期（OR = 1.76，P = 0.029）和淋巴结转移（OR = 4.09，P <0.001）相关。多变量生存分析表明，CD44表达与肿瘤特异性生存，总体生存以及无复发/无复发生存无关，但与疾病衰竭相关（HR = 2.912，95％CI = 1.51-5.61）。从TCGA数据中未发现CD44表达与临床病理特征和总生存率之间的关系。我们的发现表明CD44表达可能与膀胱癌的进展，转移和疾病衰竭相关。然而，还需要进一步的大规模研究。CI：置信区间；CSC：癌症干细胞；EMT：上皮-间质转化；人力资源：危险比率；OR：赔率；TCGA：《癌症基因组图集》。和复发/无复发生存率，但与疾病衰竭相关（HR = 2.912，95％CI = 1.51-5.61）。从TCGA数据中未发现CD44表达与临床病理特征和总生存率之间的关系。我们的发现表明CD44表达可能与膀胱癌的进展，转移和疾病衰竭相关。然而，还需要进一步的大规模研究。CI：置信区间；CSC：癌症干细胞；EMT：上皮-间质转化；人力资源：危险比；OR：赔率；TCGA：《癌症基因组图集》。和复发/无复发生存率，但与疾病衰竭相关（HR = 2.912，95％CI = 1.51-5.61）。从TCGA数据中未发现CD44表达与临床病理特征和总生存率之间的关系。我们的发现表明CD44表达可能与膀胱癌的进展，转移和疾病衰竭相关。然而，还需要进一步的大规模研究。CI：置信区间；CSC：癌症干细胞；EMT：上皮-间质转化；人力资源：危险比；OR：赔率；TCGA：《癌症基因组图集》。我们的发现表明CD44表达可能与膀胱癌的进展，转移和疾病衰竭相关。然而，还需要进一步的大规模研究。CI：置信区间；CSC：癌症干细胞；EMT：上皮-间质转化；人力资源：危险比率；OR：赔率；TCGA：《癌症基因组图集》。我们的发现表明CD44表达可能与膀胱癌的进展，转移和疾病衰竭相关。然而，还需要进一步的大规模研究。CI：置信区间；CSC：癌症干细胞；EMT：上皮-间质转化；人力资源：危险比；OR：赔率；TCGA：《癌症基因组图集》。